Omeros Corporation (OMER)
| Market Cap | 1.33B +166.3% |
| Revenue (ttm) | 38.42M |
| Net Income | 124.83M |
| EPS | 1.57 |
| Shares Out | 72.39M |
| PE Ratio | 11.68 |
| Forward PE | 18.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 104,474 |
| Open | 18.08 |
| Previous Close | 17.83 |
| Day's Range | 17.86 - 18.40 |
| 52-Week Range | 6.24 - 21.24 |
| Beta | 2.99 |
| Analysts | Buy |
| Price Target | 27.50 (+49.86%) |
| Est. Earnings | Nov 16, 2026 |
About OMER
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for OMER stock is "Buy." The 12-month stock price target is $27.5, which is an increase of 49.86% from the latest price.
News
Omeros selloff on CHMP decision overdone, says H.C. Wainwright
H.C. Wainwright views the weakness in Omeros (OMER) shares following this morning’s negative Committee for Medicinal Products for Human Use opinion as overdone. The firm sees a buying opportunity ahea...
Omeros receives negative CHMP opinion on MAA for narsoplimab
Omeros (OMER) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on the company’s marketing authorization application for nars...
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opin...
Cantor upgrades Omeros on better than expected Yartemlea launch
Cantor Fitzgerald upgraded Omeros (OMER) to Overweight from Neutral with a $22 price target The left the company’s Q2 report with the belief that Yartemlea is having a much better…
Omeros upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders upgraded Omeros (OMER) to Overweight from Neutral with a $22 price target
Omeros reports Q2 adjusted EPS 2c vs (24c) last year
Reports Q2 revenue $32.2M, consensus $12.67M. “We are very pleased with the strong momentum and growing market acceptance in the first full quarter of YARTEMLEA’s commercial launch,” said Gregory A.
Omeros Earnings Call Transcript: Q2 2026
YARTEMLEA achieved $32.2M in gross sales and $13.2M net income in its first full quarter, with strong adoption and positive cash flow. Capital structure was strengthened through share and note repurchases, and CMS granted favorable reimbursement. The company expects continued growth and aims for cash flow positivity by mid-2027.
Omeros Earnings release: Q2 2026
Omeros released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Omeros Quarterly report: Q2 2026
Omeros has published its Q2 2026 quarterly earnings report on August 12, 2026.
Omeros Corporation Reports Second Quarter 2026 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: S...
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Om...
Omeros grants new technology add-on payment status to Yartemlea
Omeros (OMER) Corporation announced that the Centers for Medicare & Medicaid Services, CMS, has granted New Technology Add-On Payment, NTAP, status for Yartemlea under the Fiscal Year 2027 Hospital In...
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLE...
AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating on Omeros (OMER) after AstraZeneca (AZN) disclosed that the Phase 3 study of ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopat...
Omeros up 11% to $10.89 after AstraZeneca study failure
10:11 EDT Omeros (OMER) up 11% to $10.89 after AstraZeneca (AZN) study failure
Omeros Corporation Investigated by the Portnoy Law Firm
LOS ANGELES, July 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Omeros Corporation , (“ Omeros " or the "Company") ( NASDAQ : OMER) investors that the firm has initiated an investigation ...
Omeros stock crashes on regulatory setback: buy the dip?
Omeros Corp (OMER) stock is tumbling on Friday morning following a major regulatory setback in Europe that has caught investors off guard. Investors are bailing on OMER mostly because the European Med...
Omeros price target lowered to $33 from $40 at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes lowered the firm’s price target on Omeros (OMER) to $33 from $40 and keeps a Buy rating on the shares after the “disappointing” negative CHMP…
Omeros announces CHMP adopts negative opinion on MAA for narsoplimab
Omeros (OMER) Corporation announced an update on the review by the Committee for Medicinal Products for Human Use of the European Medicines Agency of the company’s marketing authorization application ...
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
Omeros Transcript: AGM 2026
The meeting approved all proposals, including director elections and compensation plans, and highlighted a transformative year with the YARTEMLEA launch, strengthened financials, and pipeline progress. Management addressed shareholder questions on product adoption, competition, and capital strategy.
Omeros Announces Webcast Details for Annual Meeting of Shareholders
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, J...
Omeros trading halted, volatility trading pause
09:32 EDT Omeros (OMER) trading halted, volatility trading pause
Omeros Earnings Call Transcript: Q1 2026
YARTEMLEA's U.S. launch drove $9.9M in Q1 net revenue with rapid adoption and strong payer support. Novo Nordisk deal secured $240M upfront, and the company ended Q1 with $135.3M in cash. CMS J-code and NTAP are expected to further boost access and reimbursement.